The prognostic significance of cerebrospinal fluid in multiple sclerosis

Associations of HLA DRB1 Alleles with Igg Oligoclonal Bands and Their Influence on Multiple Sclerosis Course and Disability Status

“…Oligoclonal bands present in CSF increased the possibility for RR MS form to become progressive in all the cases analysed except when HLA DRB1 * 08 allele was detected. On the basis of this finding, it might be presumed, that OCBs could be considered as a marker related to the disease course conversion [18,19,20] in MS.…”

“…These differences may be related to the both geographical location and ethnic features, as well as immunogenetic factors, that influence intrathecal humoral immune function [11][12][13][14][15][16][17]. Opinions about OCBs impact on MS course are controversialdetection of OCBs could be associated with more aggressive course of the disease [13,[18][19][20][21], however, according to other sources, OCBs are related to slower MS progression, better course and lower disability level, as well as female sex [14].…”

Cerebrospinal fluid analysis and the determination of oligoclonal bands

“…On the prognostic side, the revived association between absence of CSF OCB and benign MS prognosis [16], has not been confirmed [17]. Moreover, some studies suggested that CSF OCBs of the IgM isotype associate with (a) aggressive MS forms [18], (b) better responses to immunotherapies [19], (c) lower risks of developing progressive multifocal leukoencephalopathy in patients on natalizumab [20], and (d) higher probability of reaching EDSS scores of 3.0/4.0 10 years after onset [21].…”

Paramètres cliniques, biochimiques et d’imagerie prédictifs de I’ évolution de la sclérose en plaques

“…83,84 Bien qu'elles n'aient pas encore été utilisées pour prédire l'évolution de la maladie, elles pourraient permettre d'orienter les décisions thérapeutiques. l'importance des Bo lgG est controversée ; alors que quelques études affirment que l'absence de Bo lgG est corrélée à une progression plus lente de handicap 85 , d'autres suggèrent que les Bo seules ne prédisent pas l'évolution de la maladie 86,87 . des problèmes avec les tests des Bo en laboratoire ont été décrits par Rauchway et al qui ont découvert que sur les 225 laboratoires américains évalués, uniquement 61 (27 %) effectuaient les tests des Bo conformément aux recommandations de la conférence de consensus.…”